Yasko et al. tested whether rhBMP-2, a pure recombinant protein, could heal a critical-size segmental bone defect in an orthotopic (bone) location. Two doses (11 μg and 1.4 μg) were implanted into 5-mm rat femoral defects on a demineralized bone matrix carrier. Outcomes were assessed radiographically, histologically, and biomechanically over 9 weeks.
Before this paper, osteoinductive proteins had only been tested as crude, partially purified bone extracts in ectopic (non-bone) sites. Whether a single, chemically defined recombinant protein could drive union across a load-bearing skeletal defect in an orthotopic location was unknown.
This study answered that question directly. A pure recombinant protein, at the right dose and with a suitable carrier, can heal a defect that predictably fails to unite in over 90% of untreated cases.
The dose-response finding is the most immediately applicable takeaway: bone formation occurred at both doses, but union required the higher dose. Biologic activity alone is not enough — you need sufficient signal to cross the threshold from bone formation to functional bridging.
This preclinical work established the biological and biomechanical rationale that ultimately supported FDA approval of rhBMP-2 (INFUSE Bone Graft) for specific spine fusion and open tibial shaft fracture indications. The carrier delivery concept validated here. Retaining BMP at the defect site to recruit local progenitor cells. Remains central to how BMP products are formulated today.
Yasko et al. tested whether rhBMP-2, a pure recombinant protein, could heal a critical-size segmental bone defect in an orthotopic (bone) location. Two doses (11 μg and 1.4 μg) were implanted into 5-mm rat femoral defects on a demineralized bone matrix carrier. Outcomes were assessed radiographically, histologically, and biomechanically over 9 weeks.
Before this paper, osteoinductive proteins had only been tested as crude, partially purified bone extracts in ectopic (non-bone) sites. Whether a single, chemically defined recombinant protein could drive union across a load-bearing skeletal defect in an orthotopic location was unknown.
This study answered that question directly. A pure recombinant protein, at the right dose and with a suitable carrier, can heal a defect that predictably fails to unite in over 90% of untreated cases.
The dose-response finding is the most immediately applicable takeaway: bone formation occurred at both doses, but union required the higher dose. Biologic activity alone is not enough — you need sufficient signal to cross the threshold from bone formation to functional bridging.
This preclinical work established the biological and biomechanical rationale that ultimately supported FDA approval of rhBMP-2 (INFUSE Bone Graft) for specific spine fusion and open tibial shaft fracture indications. The carrier delivery concept validated here. Retaining BMP at the defect site to recruit local progenitor cells. Remains central to how BMP products are formulated today.